#PANKUBreast01
Ph III results for iza bren (bispecific EGFR/HER3 ADC) vs TPC chemo, in previously treated HR +/HER- MBC
🔹mPFS: 4.0 vs. 8.1 mo, HR 0.41
🔹 ORR: 20% vs 40%
🔹 DoR: 4.2 vs. 6.9 mo
🔹 ILD: only 1.1% & all grade 1/2
#ESMO26 #ESMOAmbassadors
1347 views · 20 likes · 9 reposts · 0 replies
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.orgExtended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.orgSource: Erika Hamilton, MD, FASCO · x.com